Valuation : Alkermes plc

Market Cap 8.01B 6.91B 6.51B 5.93B 11.08B 756B 11.16B 77.03B 29.89B 387B 30.06B 29.4B 1,270B P/E 2026 *
-93.5x
P/E 2027 * 65.7x
Enterprise Value 8.75B 7.55B 7.11B 6.48B 12.11B 827B 12.2B 84.18B 32.67B 423B 32.86B 32.14B 1,388B EV / Sales 2026 *
4.79x
EV / Sales 2027 * 4.46x
Free-Float
89.45%
Yield 2026 *
-
Yield 2027 * -
1 day+1.10%
1 week-2.93%
Current month+1.55%
1 month-2.59%
3 months+15.49%
6 months+57.75%
Current year+70.55%
1 week 46.46
Extreme 46.46
48.82
1 month 46.46
Extreme 46.46
51.66
Current year 27
Extreme 27
55.67
1 year 25.16
Extreme 25.165
55.67
3 years 22.01
Extreme 22.01
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 53 01/08/2026
Director of Finance/CFO 53 15/09/2025
Chief Tech/Sci/R&D Officer 58 30/05/2017
Director TitleAgeSince
Chairman 64 01/09/2011
Director/Board Member 74 26/05/2016
Director/Board Member 63 30/03/2018
Date Insider Type Main position Quantity % Market Cap. Importance
1/9/26 Exercice

Chief Technology Officer

19,000 0.0113%
17/8/26 Sell

Executive/Senior Manager

-7,576 0.0045%
5/8/26 Free

Chief Executive Officer

217,534 0.1297%
Change 5-day change 1-year change 3-year change Capi.($)
+1.10%-2.93%+62.31%+63.03% 8.01B
-0.39%-1.33%+1.75%+17.22% 50.14B
-0.30%-2.88%+429.29%+496.95% 44.85B
+2.13%+0.89%+43.59%+17.61% 43.43B
+0.87%-3.73%+8.96%+73.17% 41.14B
-0.90%-3.67%+14.26%+48.44% 32.92B
+2.71%+6.82% - - 17.56B
+1.68%-4.20%+25.28%+116.83% 16.55B
+0.93%+0.63%+16.86%+29.29% 14.65B
+3.34%-1.13%+80.94%+39.19% 13.93B
Average +1.12%-1.06%+75.92%+100.19% 28.32B
Weighted average by Cap. +0.75%-1.26%+91.73%+120.22%

Financials

2026 *2027 *
Net sales 1.82B 1.57B 1.48B 1.35B 2.53B 172B 2.54B 17.56B 6.81B 88.14B 6.85B 6.7B 290B 1.94B 1.68B 1.58B 1.44B 2.69B 184B 2.71B 18.71B 7.26B 93.93B 7.3B 7.14B 309B
Net income -89.92M -77.57M -73.08M -66.58M -124M -8.49B -125M -865M -336M -4.34B -338M -330M -14.27B 120M 104M 97.76M 89.07M 166M 11.36B 168M 1.16B 449M 5.81B 452M 442M 19.08B
Net Debt 744M 642M 605M 551M 1.03B 70.27B 1.04B 7.16B 2.78B 35.93B 2.79B 2.73B 118B 670M 578M 544M 496M 927M 63.28B 934M 6.45B 2.5B 32.36B 2.52B 2.46B 106B
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
02/09/26 USD 47.72 +1.10% 1,566,413
01/09/26 USD 47.20 +0.45% 1,351,261
31/08/26 USD 46.99 -0.89% 1,440,889
28/08/26 USD 47.41 -3.05% 1,429,292
27/08/26 USD 48.90 -0.53% 2,119,395
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
47.72USD
Average target price
56.00USD
Spread / Average Target
+17.35%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKS Stock